Pasar al contenido principal

MODULADORES DE MERCS: DE HERRAMIENTAS FARMACOLOGICAS A CANDIDATOS A FARMACO PARA ENFERMEDADES NEURODEGENERATIVAS

PID2024-159248OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para la Investigación y el Desarrollo Experimental
Subprograma Subprograma Estatal de Generación de Conocimiento Científico-Técnico y Desarrollo Experimental
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Innovative therapies under clinical development for ALS treatment: small molecules, Expert Opinion on Investigational Drugs 1-17. doi: 10.1080/13543784.2026.2667249.

  • Martinez-Gonzalez, Loreto
  • Sanchez-Santos, Cecilia
  • Huang, Chi-Chen Sarah
  • Gil, Carmen
  • Martinez, Ana
Introduction: The clinical trial landscape for Amyotrophic Lateral Sclerosis (ALS) is a rapidly evolving field, characterized by significant obstacles but also by an increasing volume of novel therapeutics entering clinical research. Expanding on our 2022 work, this review examines the current state of the ALS clinical pipeline. Given the high volume of ongoing trials, the diversity of their biological targets and the nature of their therapeutic approaches, we focus this comprehensive update in providing a comprehensive overview of the current state of small-molecule development, focusing on agents that have entered or progressed through clinical evaluation since 2022 to the end of 2025. Areas covered: Clinical trials for ALS registered within the United States (ClinicalTrials.gov) and European Union (EU Clinical Trials Register/CTIS) databases have been systematically reviewed and are detailed in this report. Expert opinion: The implementation of advanced clinical trial platforms has introduced more efficient, adaptive strategies, leading to a significant increase in the breadth of explored therapies for ALS. Furthermore, the advent of precision medicine, powered by Artificial Intelligence (AI) for enhanced patient selection and stratification, offers a critical pathway toward overcoming the challenges posed by this severe and heterogeneous disease, This manuscript was funded by CSIC [BILAT23016]; AEI, Spain [PID2024-159248OB-I00]; Instituto de Salud Carlos III CIBERNED, [CB18/05/00040] and Fundación HNA. C.S.-S. is funded by MCIU [FPU21/01392], Peer reviewed, Sin experimentacion animal ni uso de NAMs